Hydromorphone controlled release - Pain Therapeutics

Drug Profile

Hydromorphone controlled release - Pain Therapeutics

Alternative Names: PTI 202

Latest Information Update: 14 Oct 2014

Price : $50

At a glance

  • Originator DURECT Corporation; Pain Therapeutics
  • Developer Pain Therapeutics
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 07 Aug 2014 Phase-I clinical trials in Pain (Abuse-resistant) in USA (PO)
  • 31 Oct 2013 Pfizer (formerly King Pharmaceuticals) terminates its licence for PTI 202
  • 31 Oct 2013 Suspended - Phase-I for Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top